SeaStar Medical Holding Corporation (ICU)
The price, the headline numbers and the latest news, in one place.
SeaStar Medical Holding Corporation (ICU) Stock Price, Analysis & Data
| Bid | 2.14 |
| Market Cap | 12.7M |
| Revenue (ttm) | 1.71M |
| Net Income (ttm) | -13.6M |
| -1.04 | |
| -1.82 | |
| n/a | |
| -1.12 | |
| P/B (ttm) | 2.86 |
| P/S (ttm) | 7.41 |
| Earnings Date | n/a |
| Ask | 3.69 |
| Volume | 85,377 |
| Avg. Volume (20D) | 87,351 |
| Open | 2.98 |
| Previous Close | 2.99 |
| Day's Range | 2.87 - 3.03 |
| 52-Week Range | 2.07 - 12.50 |
| Analyst | Buy |
| Price Target | 10 (247.22%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ICU
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for ped...
Financial Performance
In 2025, SeaStar Medical's revenue was 1.23M, an increase of 814.07% compared to the previous year's 135K. Earnings were -12.15M, a decrease of -51.07%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for ICU stock is "Buy". The 12-month stock price forecast is 10, which is upside of 247.22% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $495K misses estimates by $0, with 68.94% YoY growth.
- EPS of -0.91 exceeds estimates by 0.06, with 49.44% YoY growth.
